1920 Yonge Street
Toronto, ON M4S 3E2
Full Time Employees: 5
|Dr. Neil R. Cashman M.D.||Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director||99k||N/A||1952|
|Mr. Daniel E. Geffken M.B.A., MBA||Chief Financial Officer||122.28k||N/A||1957|
|Mr. Gavin T. Malenfant||Chief Operating Officer||53.32k||N/A||1962|
|Dr. Johanne Kaplan Ph.D.||Chief Devel. Officer||357.49k||N/A||N/A|
|Dr. Gail M. Farfel Ph.D.||Chief Exec. Officer||N/A||N/A||1964|
|Dr. Ernest D. Bush Ph.D.||Head of Pharmacology/Toxicology & Sr. Consultant||N/A||N/A||N/A|
|Dr. David Wishart Ph.D.||Chief Physics Officer||N/A||N/A||N/A|
|Mr. Dennis Chen Ph.D.||Head of Manufacturing & Sr. Consultant||N/A||N/A||N/A|
|Dr. Larry Douglas Altstiel M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1950|
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.